Unpredictable Effects of Short Term Marihuana (Cannabis) Use in a Male: Gynecomastia and Oligoasthenospermia
Keywords:
Marihuana, cannabis, gynecomastia, oli-goasthenospermiaAbstract
We aimed to present a case with oligoasthenospermia and gynecomastia after short term use of marihuana (cannabis).
Case: Thirty one years-old male admitted with complaint of sensation of mass in his left breast for the last 20 days. He was using cannabis for 15 days before noticing the mass. At physical examination; he had a subareolar non-tender mass in his left breast which was approximately 50 millimeters in diameter and without signs of fixation into surrounding tissue. The patient had elevated serum estradiole levels. Sperm analysis revealed decreased sperm count and loss of sperm motility. Breast sonography revealed a hypoechoic mass 45x35x25 millimeters in diameters in his left breast. Abdominal and scrotal sonographic examinations were normal. Total excision of the defined mass revealed hypertrophic mammary glands with cystic dilatations of several ductal structure in a fibroadipose tissue. There was no sign of atypia and or dysplasia. Gynecomastia was diagnosed and no further treatment was planned. He was called for routine follow up. During the next one year, he did not use cannabis and gynecomastia did not reappear. His control serum estradiol levels were decreased to normal ranges. Moreover; control sperm analyses were also evaluated as nearly normal. This case suggests that even short term use of cannabis can lead to gynecomastia and oligoasthenospermia.
References
Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001; 56: 10591068.
Ögel K, Uğuz Ş, Sır A, ve ark. Türkiye’de İlköğretim ve Ortaöğretim gençliği arasında esrar kullanım yaygınlığı. Bağımlılık Dergisi 2003; 4: 15-19.
Hibell B, Anderson B, Bjarnason T, et al. Alcohol and other drug use among students in 26 European countries. The Swedish Couincil for information on alcohol and other drugs, CAN. Couincil of Europa., Co-operation group to combat drug abuse and illicit trafficing in drug (Pompidou Group) 1995.
Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet. 1989; 16: 1-26.
Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1-20.
Maykut MO. Health consequences of acute and chronic marihuana use. Prog Neuropsychophar-macol Biol Psyhchiatry 1985; 9: 209-238.
Nahas GG, Frick HC, Lattimer JK, Latour C, Harvey D. Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa. Hum Psychopharmacol. 2002; 17: 103-113.
Nahas GG. Toxicology and pharmacology. In: Nahas GG, ed. Marijuana in Science and Medicine. New York: Raven Press, 1984; 109-246.
Dalterio S, Steger R, Mayfield D, Bartke A. Early cannabinoid exposure influences neuroendocrine and reproductive functions in mice: II. Postnatal effects. Pharmacol Biochem Behav 1984; 20: 115-123.
Dalterio SL, deRooij DG.Maternal cannabinoid exposure. Effects on spermatogenesis in male offspring. Int J Androl 1986; 9: 250-258.
Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-649.
Copeland KC, Underwood LE, Van Wyk JJ. Marihuana smoking and pubertal arrest. J Pediatr 1980; 96: 1079-1080.
Harmon J, Aliapoulios MA. Gynecomastia in marihuana users. N Engl J Med 1972; 287: 936-1080.
Wright DJ, Pearl M. Knowlodge and experience of young people regarding drug misuse, 1969-94. BMJ 1995; 309:20-24.
Ashton CH. Cannabis: Clinical and Pharmacological Aspects. Department of Health Report for the Advisory Council on the Misuse of Drugs, 1998.
Musty RE, Reggio P, Consroe P. A review of recent advances in cannabinoid research and the 1994 international symposium on cannabis and the cannabinoids. Life Sci 1995; 56: 1933-1940.
Herkenham M. Localization of cannabinoid receptors in brain and periphery. Pertwee R (editor). Cannabinoid Receptors. New York, Academic Press 1995; 145-166.
Adams IB, Martin BR. Cannabis; pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1584-1614.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
Stella N. How might cannabinoids influence sexual behavior? Proc Natl Acad Sci USA 2001; 3: 793- 795.
Grazer F. Body Counturing. McCarthy JG (editor). Plastic Surgery, Philadelphia: WB Saunders Company 1990; 6: 3964-4028.
McKinney P. Gynecomastia. Aston SJ, Beasley RW, Thorne CHM (editors). Grabb and Smith’s Plastic Surgery, 5th ed, Philadelphia: Lippincott – Raven. 1997: 753-757.
Charlson HE, Ippoliti AF. Cimetidine, an H2-anti-histamine, stimulates prolactin secretion in man. J Clin Endocrinol Metab 1977; 45: 367-369.
Glass AR. Gynecomastia. Endocrinol Metab Clin North Am 1994; 23: 825-837.
Cates W Jr, Pope NJ. Gynecomastia and cannabis smoking. A nonassociation among US Army soldiers. Am J Surg 1977; 134: 613-615.
Joshi A, Kapila K, Werma K. Fine needle aspiration cytology in the management of male breast masses. Acta Cytol 1999; 43: 334-338.
Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. Larsen PR, Kronenberg HM, Melmed S, Polosky KS (editors). Williams Textbook of Endocrinology, Tenth ed, Philadelphia: Saunders. 2003: 709-769
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Dependence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
...